Braun Stacey Associates Inc Altimmune, Inc. Transaction History

Braun Stacey Associates Inc

  • $2.53 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 25, 2022
SELL
$8.69 - $12.48 $6.19 Million - $8.88 Million
-711,818 Closed
0 $0
Q3 2021

Dec 01, 2021
BUY
$8.43 - $16.81 $24,362 - $48,580
2,890 Added 0.41%
711,818 $8.05 Million
Q2 2021

Jul 23, 2021
BUY
$9.85 - $16.46 $6.98 Million - $11.7 Million
708,928 New
708,928 $6.98 Million

Others Institutions Holding ALT

# of Institutions
185
Shares Held
44.4M
Call Options Held
1.1M
Put Options Held
647K
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $330M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Braun Stacey Associates Inc Portfolio

Follow Braun Stacey Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braun Stacey Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Braun Stacey Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email